Beijing Hotgen Biotech Co (688068.SS) Stock Price

Beijing Hotgen Biotech Co Price

SSE·CLOSED
70.63
​
Market closed

Revenue has compounded at 14.3% per year over the past 9 years to 407.69 M CNY. Earnings per share have grown at 3.7% per year over the last 7 years. Beijing Hotgen Biotech Co's net margin stands at -51.6%, down from 40.7% several years earlier. Beijing Hotgen Biotech Co currently offers a dividend yield of about 0.28%.

Beijing Hotgen Biotech Co stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Beijing Hotgen Biotech Co business model & stock analysis

Beijing Hotgen Biotech Co., Ltd. generates revenue through the development and manufacturing of in-vitro diagnostic, point-of-care-testing, and biodefense products. The firm's product portfolio primarily consists of in vitro diagnostic reagents, in vitro diagnostic instruments, and biological raw materials. These offerings are designed to address clinical needs in areas such as liver cancer, hepatitis, cardiovascular and cerebrovascular diseases, and inflammatory infections. Additionally, the products serve public safety applications including biosafety, food safety, and disease control and emergency response. The company operates in both domestic and overseas markets, selling its solutions to entities involved in clinical healthcare and public safety sectors. By providing specialized diagnostic tools and biological materials, Beijing Hotgen Biotech Co., Ltd. supports medical diagnosis and emergency response efforts globally. The business model relies on the direct sale of these manufactured goods to customers who require advanced diagnostic capabilities for disease detection and safety monitoring.

Frequently asked questions about Beijing Hotgen Biotech Co

5 analysts currently rate the Beijing Hotgen Biotech Co stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Beijing Hotgen Biotech Co to generate revenue of 488.66 M CNY and earnings per share of -0.52 CNY.

Converted at the current exchange rate, the Beijing Hotgen Biotech Co share trades at 9.50 EUR (70.63 CNY).

The Beijing Hotgen Biotech Co share (688068.SS) is listed on 1 stock exchanges, including: Shanghai (688068.SS).

The expected revenue of Beijing Hotgen Biotech Co is 488.66 M CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Beijing Hotgen Biotech Co is -56.76 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Beijing Hotgen Biotech Co is currently -137.09. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Beijing Hotgen Biotech Co stock.

The price-to-sales ratio (P/S) of Beijing Hotgen Biotech Co is currently 15.92. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Beijing Hotgen Biotech Co stock.

The Eulerpool Quality Score for Beijing Hotgen Biotech Co is 1/10.

The ISIN of Beijing Hotgen Biotech Co is CNE100003P82. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Beijing Hotgen Biotech Co is 688068.SS. The ticker symbol is used to trade Beijing Hotgen Biotech Co shares on the stock exchange.

Fair ValueTerminal
65.69 CNY
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Life Sciences Tools & Services
Number of shares
Employees
Revenue per Employee
345,796.27 CNY
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Currency
CNY
Initial public offering
Sep 30, 2019
ISIN
CNE100003P82
Cusip
Y0R9X5107
Market capitalization
6.36 B CNYMid Cap
52-Week Range
PEG
—
P/E ratio
P/Ee 2026
-137.09
P/Ee 2027
882.87
P/Ee 2028
98.10
P/Se
15.92
EV/EBIT
—
P/B Ratio
2.17
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-7.19 %
Dividend
Dividend yield
0.00 %
Est. Dividend Yield
0.28 %
Payout Ratio
24.76 %
Dividend growth Ø5Y
—
Dividend payments per year
1
Dividend paid since
0 years
Dividend not reduced since
0 years
Dividend increased since
0 years
Dividend withholding tax
10.00 %
Last updated Oct 30, 2026, 1:56 AM

Beijing Hotgen Biotech Co Peer Group

Beijing Hotgen Biotech Co Ticker

SHH · 688068.SS

Beijing Hotgen Biotech Co FIGI

688068:CH · BBG00NTXM8M9688068:CG · BBG00NTXM8N8688068:C1 · BBG01FRBMJP8

All fundamentals and in-depth analysis of Beijing Hotgen Biotech Co

Our stock analysis for Beijing Hotgen Biotech Co stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Beijing Hotgen Biotech Co. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.